Search

Your search keyword '"Rezvani, Andrew"' showing total 561 results
Start Over Author "Rezvani, Andrew"
561 results on '"Rezvani, Andrew"'

1. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results

Author

Schultz, Liora M., Jeyakumar, Nikeshan, Kramer, Anne Marijn, Sahaf, Bita, Srinagesh, Hrishi, Shiraz, Parveen, Agarwal, Neha, Hamilton, Mark, Erickson, Courtney, Jacobs, Ashley, Moon, Jennifer, Baggott, Christina, Arai, Sally, Bharadwaj, Sushma, Johnston, Laura J., Liedtke, Michaela, Lowsky, Robert, Meyer, Everett, Negrin, Robert, Rezvani, Andrew, Shizuru, Judy, Sidana, Surbhi, Egeler, Emily, Mavroukakis, Sharon, Tunuguntla, Ramya, Gkitsas-Long, Nikolaos, Retherford, Aidan, Brown, Annie Kathleen, Gramstrap-Petersen, Anne-Louise, Ibañez, Raquel Martin, Feldman, Steven A., Miklos, David B., Mackall, Crystal L., Davis, Kara L., Frank, Matthew, Ramakrishna, Sneha, and Muffly, Lori

Published
2024
Full Text
View/download PDF

2. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Author

Lin, Chenyu, Schwarzbach, Aurelie, Sanz, Jaime, Montesinos, Pau, Stiff, Patrick, Parikh, Suhag, Brunstein, Claudio, Cutler, Corey, Lindemans, Caroline, Hanna, Rabi, Koh, Liang, Jagasia, Madan, Valcarcel, David, Maziarz, Richard, Keating, Amy, Hwang, William, Rezvani, Andrew, Karras, Nicole, Fernandes, Juliana, Rocha, Vanderson, Badell, Isabel, Ram, Ron, Schiller, Gary, Volodin, Leonid, Walters, Mark, Hamerschlak, Nelson, Cilloni, Daniela, Frankfurt, Olga, McGuirk, Joseph, Kurtzberg, Joanne, Sanz, Guillermo, Simantov, Ronit, and Horwitz, Mitchell

Subjects
Allogeneic stem cell transplantation, Clinical trial, Cord blood, Ex vivo expansion, Long-term follow-up, Humans, Follow-Up Studies, Prospective Studies, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Multicenter Studies as Topic
Abstract

Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has demonstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early benefits of omidubicel have been established, long-term outcomes remain unknown. We report on a planned pooled analysis of 5 multicenter clinical trials including 105 patients with hematologic malignancies or sickle cell hemoglobinopathy who underwent omidubicel transplantation at 26 academic transplantation centers worldwide. With a median follow-up of 22 months (range, .3 to 122 months), the 3-year estimated overall survival and disease-free survival were 62.5% and 54.0%, respectively. With up to 10 years of follow-up, omidubicel showed durable trilineage hematopoiesis. Serial quantitative assessments of CD3+, CD4+, CD8+, CD19+, CD116+CD56+, and CD123+ immune subsets revealed median counts remaining within normal ranges through up to 8 years of follow-up. Secondary graft failure occurred in 5 patients (5%) in the first year, with no late cases reported. One case of donor-derived myeloid neoplasm was reported at 40 months post-transplantation. This was also observed in a control arm patient who received only unmanipulated UCB. Overall, omidubicel demonstrated stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up.

Published
2023

3. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

Author

Klysz, Dorota Danuta, Gkitsas-Long, Nikolaos, Bacigalupi, Juliana, Iglesias, Maria, Crawford, Emma, Nichols, Linnea, Cunanan, Kristen, Tamaresis, John, Spiegel, Jay Y., Ehlinger, Zachary, Kuo, Adam, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen Kai, Bharadwaj, Sushma, Dahiya, Saurabh, Smith, Melody, Schultz, Liora M., Ramakrishna, Sneha, Davis, Kara L., Tunuguntla, Ramya, Frank, Matthew J, Baird, John H, Kramer, Anne Marijn, Srinagesh, Hrishikesh K, Patel, Shabnum, Brown, Annie Kathleen, Oak, Jean S, Younes, Sheren F, Natkunam, Yasodha, Hamilton, Mark P, Su, Yi-Jiun, Agarwal, Neha, Chinnasamy, Harshini, Egeler, Emily, Mavroukakis, Sharon, Feldman, Steven A, Sahaf, Bita, Mackall, Crystal L, Muffly, Lori, and Miklos, David B

Published
2024
Full Text
View/download PDF

4. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report.

Author

Bankova, Andriyana, Caveney, Joseph, Yao, Bin, Ramos, Teresa, Bögeholz, Jan, Heydari, Kartoosh, Diaz, Nery, Jackson, Marin, Lowsky, Robert, Brown, Janice, Johnston, Laura, Rezvani, Andrew, Frank, Matthew, Muffly, Lori, Weng, Wen-Kai, Sidana, Surbhi, Negrin, Robert, Miklos, David, Shiraz, Parveen, Meyer, Everett, Shizuru, Judith, and Arai, Sally

Subjects
Cryopreserved allografts, Engraftment failure, Graft composition, Reduced-intensity conditioning, COVID-19, Cryopreservation, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Pandemics, Retrospective Studies
Abstract

In response to the widespread COVID-19 pandemic, cryopreservation of allogeneic donor apheresis products was implemented to mitigate the challenges of donor availability and product transport. Although logistically beneficial, the impact of cryopreservation on clinical outcomes and graft composition remains unclear. In this study, we compared outcomes and graft composition with cryopreserved versus fresh allografts in the setting of allogeneic hematopoietic cell transplantation (allo-HCT). We retrospectively analyzed the clinical outcomes of 30 consecutive patients who received cryopreserved allografts between March and August 2020 and 60 consecutive patients who received fresh allografts before the COVID-19 pandemic. Primary endpoints were hematopoietic engraftment and graft failure (GF), and secondary outcomes were overall survival (OS), relapse-free survival (RFS) and nonrelapse mortality (NRM). In addition, extended immunophenotype analysis was performed on cryopreserved and prospectively collected fresh apheresis samples. Compared with recipients of fresh allografts, both neutrophil and platelet recovery were delayed in recipients of cryopreserved reduced-intensity conditioning (RIC) allo-HCT, with a median time to engraftment of 24 days versus 18 days (P = .01) for neutrophils and 27 days versus 18 days (P = .069) for platelets. We observed primary GF in 4 of 30 patients in the cryopreserved cohort (13.3%) versus only 1 of 60 patients (1.7 %) in the fresh cohort (P = .03). Cryopreserved RIC allo-HCT was associated with significantly lower median total, myeloid, and T cell donor chimerism at 1 month. OS and RFS were inferior for cryopreserved graft recipients (hazard ratio [HR], 2.16; 95% confidence interval [CI], 1.00 to 4.67) and HR, 1.90; 95% CI, 0.95 to 3.79, respectively. Using an extended immunophenotype analysis, we compared 14 samples from the cryopreserved cohort to 6 prospectively collected fresh apheresis donor samples. These analyses showed both a decrease in total cell viability and a significantly reduced absolute number of natural killer cells (CD3-CD56+) in the cryopreserved apheresis samples. In this single-institution study, we found delayed engraftment and a trend toward clinical inferiority of cryopreserved allografts compared with fresh allografts. Further evaluation of the use of cryopreserved allografts and their impact on clinical and laboratory outcomes is warranted.

Published
2022

5. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity

Author

Hamilton, Mark P., Craig, Erin, Gentille Sanchez, Cesar, Mina, Alain, Tamaresis, John, Kirmani, Nadia, Ehlinger, Zachary, Syal, Shriya, Good, Zinaida, Sworder, Brian, Schroers-Martin, Joseph, Lu, Ying, Muffly, Lori, Negrin, Robert S., Arai, Sally, Lowsky, Robert, Meyer, Everett, Rezvani, Andrew R., Shizuru, Judith, Weng, Wen-Kai, Shiraz, Parveen, Sidana, Surbhi, Bharadwaj, Sushma, Smith, Melody, Dahiya, Saurabh, Sahaf, Bita, Kurtz, David M., Mackall, Crystal L., Tibshirani, Robert, Alizadeh, Ash A., Frank, Matthew J., and Miklos, David B.

Published
2024
Full Text
View/download PDF

6. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD

Author

Bader, Cameron S., Pavlova, Anna, Lowsky, Robert, Muffly, Lori S., Shiraz, Parveen, Arai, Sally, Johnston, Laura J., Rezvani, Andrew R., Weng, Wen-Kai, Miklos, David B., Frank, Matthew J., Tamaresis, John S., Agrawal, Vaibhav, Bharadwaj, Sushma, Sidana, Surbhi, Shizuru, Judith A., Fernhoff, Nathaniel B., Putnam, Amy, Killian, Scott, Xie, Bryan J., Negrin, Robert S., and Meyer, Everett H.

Published
2024
Full Text
View/download PDF

7. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Author

Srinagesh, Hrishikesh, Jackson, Clayton, Shiraz, Parveen, Jeyakumar, Nikeshan, Hamilton, Mark, Egeler, Emily, Mavroukakis, Sharon, Kuo, Adam, Cancilla, Juancarlos, Sahaf, Bita, Agarwal, Neha, Kanegai, Alyssa, Kramer, Anne Marijn, Arai, Sally, Bharadwaj, Sushma, Dahiya, Saurabh, Hosoya, Hitomi, Johnston, Laura, Kennedy, Vanessa, Liedtke, Michaela, Lowsky, Robert, Mikkilineni, Lekha, Negrin, Robert, Rezvani, Andrew, Sidana, Surbhi, Shizuru, Judith, Smith, Melody, Weng, Wen-Kai, Feldman, Steven, Frank, Matthew J., Lee, Zachary, Tagliaferri, Mary, Marcondes, A. Mario, Miklos, David, Mackall, Crystal, and Muffly, Lori

Published
2024
Full Text
View/download PDF

8. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

Author

Epperla, Narendranath, Kumar, Ambuj, Abutalib, Syed A., Awan, Farrukh T., Chen, Yi-Bin, Gopal, Ajay K., Holter-Chakrabarty, Jennifer, Kekre, Natasha, Lee, Catherine J., Lekakis, Lazaros, Lin, Yi, Mei, Matthew, Nathan, Sunita, Nastoupil, Loretta, Oluwole, Olalekan, Phillips, Adrienne A., Reid, Erin, Rezvani, Andrew R., Trotman, Judith, Zurko, Joanna, Kharfan-Dabaja, Mohamed A., Sauter, Craig S., Perales, Miguel-Angel, Locke, Frederick L., Carpenter, Paul A., and Hamadani, Mehdi

Published
2023
Full Text
View/download PDF

9. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Author

Spinner, Michael A., Sica, R. A., Tamaresis, John S., Lu, Ying, Chang, Cheryl, Lowsky, Robert, Frank, Matthew J., Johnston, Laura J., Miklos, David B., Muffly, Lori S., Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Shizuru, Judith A., Weng, Wen-Kai, Binkley, Michael S., Hoppe, Richard T., Advani, Ranjana H., and Arai, Sally

Published
2023
Full Text
View/download PDF

10. Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.

Author

Multani, Ashrit, Allard, Libby S, Wangjam, Tamna, Sica, R Alejandro, Epstein, David J, Rezvani, Andrew R, and Ho, Dora Y

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Transplantation, Clinical Research, Infectious Diseases, Vaccine Related, Infection, Good Health and Well Being, Aged, Autopsy, Communicable Diseases, Diagnostic Errors, Hematopoietic Stem Cell Transplantation, Humans, Immunohistochemistry, Male, Middle Aged, Missed Diagnosis, Mortality, Patient Outcome Assessment, Transplant Recipients, Transplantation, Autologous, Transplantation, Homologous, Cardiovascular medicine and haematology
Abstract

Hematopoietic cell transplantation (HCT) is potentially curative for patients with hematologic disorders, but carries significant risks of infection-related morbidity and mortality. Infectious diseases are the second most common cause of death in HCT recipients, surpassed only by progression of underlying disease. Many infectious diseases are difficult to diagnose and treat, and may only be first identified by autopsy. However, autopsy rates are decreasing despite their value. The clinical and autopsy records of adult HCT recipients at our center who underwent autopsy between 1 January 2000 and 31 December 2017 were reviewed. Discrepancies between premortem clinical diagnoses and postmortem autopsy diagnoses were evaluated. Of 185 patients who underwent autopsy, 35 patients (18.8%) had a total of 41 missed infections. Five patients (2.7%) had >1 missed infection. Of the 41 missed infections, 18 (43.9%) were viral, 16 (39.0%) were fungal, 5 (12.2%) were bacterial, and 2 (4.9%) were parasitic. According to the Goldman criteria, 31 discrepancies (75.6%) were class I, 5 (12.2%) were class II, 1 (2.4%) was class III, and 4 (9.8%) were class IV. Autopsies of HCT recipients frequently identify clinically significant infectious diseases that were not suspected premortem. Had these infections been suspected, a change in management might have improved patient survival in many of these cases. Autopsy is underutilized and should be performed regularly to help improve infection-related morbidity and mortality. Illustrative cases are presented and the lessons learned from them are also discussed.

Published
2019

11. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.

Author

Meyer, Everett, Laport, Ginna, Xie, Bryan, MacDonald, Kate, Sahaf, Bita, Tang, Sai-Wen, Baker, Jeanette, Armstrong, Randall, Tate, Keri, Tadisco, Cynthia, Arai, Sally, Johnston, Laura, Lowsky, Robert, Muffly, Lori, Rezvani, Andrew, Shizuru, Judith, Weng, Wen-Kai, Sheehan, Kevin, Miklos, David, Negrin, Robert, and Heydari, Kartoosh

Subjects
Bone marrow transplantation, Cellular immune response, Clinical Trials, Transplantation, Adult, Aged, Bone Marrow Transplantation, Female, Graft vs Host Disease, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, T-Lymphocytes, Regulatory, Tissue Donors, Young Adult
Abstract

BACKGROUNDIn preclinical murine and early clinical studies of hematopoietic cell transplantation, engineering of donor grafts with defined ratios of CD4+CD25+FoxP3+ Tregs to conventional T cells (Tcons) results in the prevention of graft-versus-host disease and improved immune reconstitution. The use of highly purified primary graft Tregs for direct cell infusion has potential advantages over impure immunomagnetic selection or culture expansion, but has not been tested clinically. We performed a phase I study of the timed addition of CD34-selected hematopoietic stem cells and Tregs, followed by Tcons for the treatment of patients with high-risk hematological malignancies.METHODSWe present interim evaluation of a single-center open phase I/II study of administration of human leukocyte-matched Tregs and CD34-selected hematopoietic cells, followed by infusion of an equal ratio of Tcons in adult patients undergoing myeloablative hematopoietic stem cell transplantation (HCT) for high-risk or active hematological malignancies. Tregs were purified by immunomagnetic selection and high-speed cell sorting.RESULTSHere we report results for the first 12 patients who received Tregs of between 91% and 96% purity. Greater than grade II GVHD was noted in 2 patients in the first cohort of 5 patients, who received cryopreserved Tregs, but neither acute nor chronic GVHD was noted in the second cohort of 7 patients, who received fresh Tregs and single-agent GVHD prophylaxis. Patients in the second cohort appeared to have normal immune reconstitution compared with patients who underwent transplantation and did not develop GVHD.CONCLUSIONOur study shows that the use of highly purified fresh Tregs is clinically feasible and supports continued investigation of the strategy.TRIAL REGISTRATIONClinicalTrials.gov NCT01660607.FUNDINGNIH NHBLI R01 HL114591 and K08HL119590.

Published
2019

16. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.

Author

Shah, Nirav, Ahn, Kwang, Litovich, Carlos, Fenske, Timothy, Ahmed, Sairah, Battiwalla, Minoo, Bejanyan, Nelli, Dahi, Parastoo, Bolaños-Meade, Javier, Chen, Andy, Ciurea, Stefan, Bachanova, Veronika, DeFilipp, Zachariah, Epperla, Narendranath, Farhadfar, Nosha, Herrera, Alex, Haverkos, Bradley, Holmberg, Leona, Hossain, Nasheed, Kharfan-Dabaja, Mohamed, Kenkre, Vaishalee, Lazarus, Hillard, Murthy, Hemant, Nishihori, Taiga, Rezvani, Andrew, DSouza, Anita, Savani, Bipin, Ulrickson, Matthew, Waller, Edmund, Sureda, Anna, Smith, Sonali, and Hamadani, Mehdi

Subjects
Age Factors, Aged, Databases, Factual, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Non-Hodgkin, Medicare, Middle Aged, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, United States
Abstract

The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged ≥65 years (older cohort; n = 446) compared with a cohort of younger NHL patients aged 55-64 years (n = 1183). We identified 1629 NHL patients undergoing a first reduced-intensity conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the United States. Cord blood or haploidentical transplants were excluded. The median age was 68 years (range 65-77) for the older cohort vs 60 years (range 55-64) in the younger cohort. The 4-year adjusted probabilities of nonrelapse mortality (NRM), relapse/progression (R/P), progression-free survival (PFS), and overall survival (OS) of the younger and older groups were 24% vs 30% (P = .03), 41% vs 42% (P = .82), 37% vs 31% (P = .03), and 51% vs 46% (P = .07), respectively. Using multivariate analysis, compared with the younger group, the older cohort was associated with increased NRM, but there was no difference between the 2 cohorts in terms of R/P, PFS, or OS. The most common cause of death was disease relapse in both groups. In NHL patients eligible for allo-HCT, there was no difference in OS between the 2 cohorts. Age alone should not determine allo-HCT eligibility in NHL, and Medicare should expand allo-HCT coverage to older adults.

Published
2018

17. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Author

Johnsrud, Andrew, Craig, Juliana, Baird, John, Spiegel, Jay, Muffly, Lori, Zehnder, James, Tamaresis, John, Negrin, Robert, Johnston, Laura, Arai, Sally, Shizuru, Judith, Lowsky, Robert, Meyer, Everett, Weng, Wen-Kai, Shiraz, Parveen, Rezvani, Andrew, Latchford, Theresa, Mackall, Crystal, Miklos, David, Frank, Matthew, and Sidana, Surbhi

Published
2021
Full Text
View/download PDF

18. CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Author

Hamilton, Mark P., primary, Sworder, Brian, additional, Alig, Stefan, additional, Good, Zinaida, additional, Boegeholz, Jan, additional, Schroers-Martin, Joseph, additional, Tamaresis, John, additional, Esfahani, Mohammad, additional, Lu, Ying, additional, Olsen, Mari, additional, Liu, Chih Long, additional, Ehlinger, Zachary, additional, Desai, Moksha, additional, Liu-Fei, Felicia, additional, Muffly, Lori S, additional, Negrin, Robert S., additional, Arai, Sally, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Meyer, Everett H., additional, Rezvani, Andrew R., additional, Shizuru, Judith A., additional, Weng, Wen-Kai, additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Bharadwaj, Sushma, additional, Smith, Melody, additional, Dahiya, Saurabh, additional, Sahaf, Bita, additional, Diehn, Max, additional, Frank, Matthew J., additional, Mackall, Crystal L., additional, Kurtz, David, additional, Miklos, David B., additional, and Alizadeh, Ash A., additional

Published
2024
Full Text
View/download PDF

19. Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open-Label Expanded Access Program (EAP)

Author

Horwitz, Mitchell, primary, Schiller, Gary J., additional, Tsai, Dr. Stephanie B., additional, Rezvani, Andrew R., additional, Maziarz, Richard T., additional, Goshen, Uri, additional, Levy, Stuart, additional, Schwarzbach, Aurelie, additional, Mazor, Dr. Roei, additional, and Stiff, Patrick J., additional

Published
2024
Full Text
View/download PDF

20. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia

Author

Muffly, Lori, Sundaram, Vandana, Chen, Connie, Yurkiewicz, Ilana, Kuo, Eric, Burnash, Sarah, Spiegel, Jay Y., Arai, Sally, Frank, Matthew J., Johnston, Laura J., Lowsky, Robert, Meyer, Everett H., Negrin, Robert S., Rezvani, Andrew R., Sidana, Surbhi, Shiraz, Parveen, Shizuru, Judith A., Weng, Wen-Kai, Liedtke, Michaela, Vempaty, Hyma T., and Miklos, David B.

Published
2021
Full Text
View/download PDF

21. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Author

Spiegel, Jay Y., Patel, Shabnum, Muffly, Lori, Hossain, Nasheed M., Oak, Jean, Baird, John H., Frank, Matthew J., Shiraz, Parveen, Sahaf, Bita, Craig, Juliana, Iglesias, Maria, Younes, Sheren, Natkunam, Yasodha, Ozawa, Michael G., Yang, Eric, Tamaresis, John, Chinnasamy, Harshini, Ehlinger, Zach, Reynolds, Warren, Lynn, Rachel, Rotiroti, Maria Caterina, Gkitsas, Nikolaos, Arai, Sally, Johnston, Laura, Lowsky, Robert, Majzner, Robbie G., Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Sidana, Surbhi, Shizuru, Judith, Weng, Wen-Kai, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Bazzano, Magali, Zhou, Jing, Mackay, Sean, Bornheimer, Scott J., Schultz, Liora, Ramakrishna, Sneha, Davis, Kara L., Kong, Katherine A., Shah, Nirali N., Qin, Haiying, Fry, Terry, Feldman, Steven, Mackall, Crystal L., and Miklos, David B.

Published
2021
Full Text
View/download PDF

24. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

Author

Baird, John H., Epstein, David J., Tamaresis, John S., Ehlinger, Zachary, Spiegel, Jay Y., Craig, Juliana, Claire, Gursharan K., Frank, Matthew J., Muffly, Lori, Shiraz, Parveen, Meyer, Everett, Arai, Sally, Brown, Janice (Wes), Johnston, Laura, Lowsky, Robert, Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Latchford, Theresa, Sahaf, Bita, Mackall, Crystal L., Miklos, David B., and Sidana, Surbhi

Published
2021
Full Text
View/download PDF

25. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

Author

Frank, Matthew J, Baird, John H, Kramer, Anne Marijn, Srinagesh, Hrishikesh K, Patel, Shabnum, Brown, Annie Kathleen, Oak, Jean S, Younes, Sheren F, Natkunam, Yasodha, Hamilton, Mark P, Su, Yi-Jiun, Agarwal, Neha, Chinnasamy, Harshini, Egeler, Emily, Mavroukakis, Sharon, Feldman, Steven A, Sahaf, Bita, Mackall, Crystal L, Muffly, Lori, Miklos, David B, Klysz, Dorota Danuta, Gkitsas-Long, Nikolaos, Bacigalupi, Juliana, Iglesias, Maria, Crawford, Emma, Nichols, Linnea, Cunanan, Kristen, Tamaresis, John, Spiegel, Jay Y., Ehlinger, Zachary, Kuo, Adam, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen Kai, Bharadwaj, Sushma, Dahiya, Saurabh, Smith, Melody, Schultz, Liora M., Ramakrishna, Sneha, Davis, Kara L., and Tunuguntla, Ramya

Abstract

Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this study.

Published
2024
Full Text
View/download PDF

29. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Author

Kahn, Justine M., Brazauskas, Ruta, Tecca, Heather R., Bo-Subait, Stephanie, Buchbinder, David, Battiwala, Minoo, Flowers, Mary E.D., Savani, Bipin N., Phelan, Rachel, Broglie, Larisa, Abraham, Allistair A., Keating, Amy K., Daly, Andrew, Wirk, Baldeep, George, Biju, Alter, Blanche P., Ustun, Celalettin, Freytes, Cesar O., Beitinjaneh, Amer M., Duncan, Christine, Copelan, Edward, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Auletta, Jeffery J., Myers, Kasiani C., Williams, Kirsten M., Page, Kristin M., Vrooman, Lynda M., Norkin, Maxim, Byrne, Michael, Diaz, Miguel Angel, Kamani, Naynesh, Bhatt, Neel S., Rezvani, Andrew, Farhadfar, Nosha, Mehta, Parinda A., Hematti, Peiman, Shaw, Peter J., Kamble, Rammurti T., Schears, Raquel, Olsson, Richard F., Hayashi, Robert J., Gale, Robert Peter, Mayo, Samantha J., Chhabra, Saurabh, Rotz, Seth J., Badawy, Sherif M., Ganguly, Siddhartha, Pavletic, Steven, Nishihori, Taiga, Prestidge, Tim, Agrawal, Vaibhav, Hogan, William J., Inamoto, Yoshihiro, Shaw, Bronwen E., and Satwani, Prakash

Published
2020
Full Text
View/download PDF

31. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood

Author

Lin, Chenyu, Sajeev, Gautam, Stiff, Patrick J., Brunstein, Claudio G., Cutler, Corey, Sanz, Guillermo, Lindemans, Caroline A., Rezvani, Andrew R., Hanna, Rabi, Koh, Liang Piu, Maziarz, Richard T., Hwang, William Y.K., Song, Yan, Liu, Qing, Manghani, Rocio, Sivaraman, Smitha, Signorovitch, James, Horwitz, Mitchell E., and Sung, Anthony D.

Published
2023
Full Text
View/download PDF

33. CT-314 Multicenter Long-Term Follow Up of Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

Author

Lin, Chenyu, Schwarzbach, Aurelie, Montesinos, Pau, Stiff, Patrick, Cutler, Corey, Parikh, Suhag, Brunstein, Claudio, Lindemans, Caroline A., Hanna, Rabi, Koh, Liang Piu, Maziarz, Richard T., Keating, Amy K., Huang, William Y.K., Rezvani, Andrew R., Valcarcel, David, Fernandes, Juliana F., Badell, Isabell S., Jagasia, Madan H., Frankfurt, Olga, Ram, Ron, McGuirk, Joseph P., Kurtzberg, Joanne, Sanz, Guillermo, Simantov, Ronit, and Horwitz, Mitchell E.

Published
2022
Full Text
View/download PDF

34. CT-039 Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood

Author

Lin, Chenyu, Sajeev, Gautam, Stiff, Patrick, Brunstein, Claudio, Cutler, Corey, Sanz, Guillermo, Lindemans, Caroline, Rezvani, Andrew, Hanna, Rabi, Koh, Liang Piu, Maziarz, Richard, Hwang, William, Song, Yan, Liu, Qing, Manghani, Rocio, Sivaraman, Smitha, Signorovitch, James, Galamidi-Cohen, Einat, Horwitz, Mitchell, and Sung, Anthony

Published
2022
Full Text
View/download PDF

35. Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies

Author

Horwitz, Mitchell, primary, Schiller, Gary, additional, Tsai, Stephanie, additional, Rezvani, Andrew, additional, Maziarz, Richard, additional, Goshen, Uri, additional, Levy, Stuart, additional, Schwarzbach, Aurelie, additional, Mazor, Roei, additional, and Stiff, Patrick, additional

Published
2023
Full Text
View/download PDF

36. Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101

Author

Brunstein, Claudio G., O'Donnell, Paul V., Logan, Brent, Dawson, Peter, Costa, Luciano, Cutler, Corey, Craig, Michael, Hogan, William, Horowitz, Mary M., Horwitz, Mitchell E., Karanes, Chatchada, Magenau, John M., Malone, Adriana, McCarty, John, McGuirk, Joseph P., Morris, Lawrence E., Rezvani, Andrew R., Salit, Rachel, Vasu, Sumithira, Eapen, Mary, and Fuchs, Ephraim J.

Published
2022
Full Text
View/download PDF

37. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

Author

Casulo, Carla, Friedberg, Jonathan W., Ahn, Kwang W., Flowers, Christopher, DiGilio, Alyssa, Smith, Sonali M., Ahmed, Sairah, Inwards, David, Aljurf, Mahmoud, Chen, Andy I., Choe, Hannah, Cohen, Jonathon, Copelan, Edward, Farooq, Umar, Fenske, Timothy S., Freytes, Cesar, Gaballa, Sameh, Ganguly, Siddhartha, Jethava, Yogesh, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard, Lazaryan, Aleksandr, Olsson, Richard F., Rezvani, Andrew R., Rizzieri, David, Seo, Sachiko, Shah, Gunjan L., Shah, Nina, Solh, Melham, Sureda, Anna, William, Basem, Cumpston, Aaron, Zelenetz, Andrew D., Link, Brian K., and Hamadani, Mehdi

Published
2018
Full Text
View/download PDF

38. Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes

Author

O'Donnell, Paul V., Brunstein, Claudio G., Fuchs, Ephraim J., Zhang, Mei-Jie, Allbee-Johnson, Mariam, Antin, Joseph H., Leifer, Eric S., Elmariah, Hany, Grunwald, Michael R., Hashmi, Hamza, Horowitz, Mary M., Magenau, John M., Majhail, Navneet, Milano, Filippo, Morris, Lawrence E., Rezvani, Andrew R., McGuirk, Joseph P., Jones, Richard J., and Eapen, Mary

Published
2022
Full Text
View/download PDF

40. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

Author

Lin, Chenyu, primary, Schwarzbach, Aurelie, additional, Sanz, Jaime, additional, Montesinos, Pau, additional, Stiff, Patrick, additional, Parikh, Suhag, additional, Brunstein, Claudio, additional, Cutler, Corey, additional, Lindemans, Caroline A., additional, Hanna, Rabi, additional, Koh, Liang Piu, additional, Jagasia, Madan H., additional, Valcarcel, David, additional, Maziarz, Richard T., additional, Keating, Amy K., additional, Hwang, William Y.K., additional, Rezvani, Andrew R., additional, Karras, Nicole A., additional, Fernandes, Juliana F., additional, Rocha, Vanderson, additional, Badell, Isabel, additional, Ram, Ron, additional, Schiller, Gary J., additional, Volodin, Leonid, additional, Walters, Mark C., additional, Hamerschlak, Nelson, additional, Cilloni, Daniela, additional, Frankfurt, Olga, additional, McGuirk, Joseph P., additional, Kurtzberg, Joanne, additional, Sanz, Guillermo, additional, Simantov, Ronit, additional, and Horwitz, Mitchell E., additional

Published
2023
Full Text
View/download PDF

42. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Author

Muffly, Lori, Pasquini, Marcelo C., Martens, Michael, Brazauskas, Ruta, Zhu, Xiaochun, Adekola, Kehinde, Aljurf, Mahmoud, Ballen, Karen K., Bajel, Ashish, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Cahn, Jean-Yves, Carabasi, Mathew, Chen, Yi-Bin, Chhabra, Saurabh, Ciurea, Stefan, Copelan, Edward, D'Souza, Anita, Edwards, John, Foran, James, Freytes, Cesar O., Fung, Henry C., Gale, Robert Peter, Giralt, Sergio, Hashmi, Shahrukh K., Hildebrandt, Gerhard C., Ho, Vincent, Jakubowski, Ann, Lazarus, Hillard, Luskin, Marlise R., Martino, Rodrigo, Maziarz, Richard, McCarthy, Philip, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Pawarode, Attaphol, Peres, Edward, Rezvani, Andrew R., Rizzieri, David, Savani, Bipin N., Schouten, Harry C., Sabloff, Mitchell, Seftel, Matthew, Seo, Sachiko, Sorror, Mohamed L., Szer, Jeff, Wirk, Baldeep M., Wood, William A., and Artz, Andrew

Published
2017
Full Text
View/download PDF

43. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial

Author

Andermann, Tessa M., Fouladi, Farnaz, Tamburini, Fiona B., Sahaf, Bita, Tkachenko, Ekaterina, Greene, Courtney, Buckley, Matthew T., Brooks, Erin F., Hedlin, Haley, Arai, Sally, Mackall, Crystal L., Miklos, David, Negrin, Robert S., Fodor, Anthony A., Rezvani, Andrew R., and Bhatt, Ami S.

Published
2021
Full Text
View/download PDF

45. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Author

Epperla, Narendranath, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Battiwalla, Minoo, Cohen, Jonathon B., Dahi, Parastoo, Farhadfar, Nosha, Farooq, Umar, Freytes, Cesar O., Ghosh, Nilanjan, Haverkos, Bradley, Herrera, Alex, Hertzberg, Mark, Hildebrandt, Gerhard, Inwards, David, Kharfan-Dabaja, Mohamed A., Khimani, Farhad, Lazarus, Hillard, Lazaryan, Aleksandr, Lekakis, Lazaros, Murthy, Hemant, Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Prestidge, Tim, Ramakrishnan, Praveen, Rezvani, Andrew R., Romee, Rizwan, Shah, Nirav N., Sureda, Ana, Fenske, Timothy S., and Hamadani, Mehdi

Published
2019
Full Text
View/download PDF

46. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era

Author

Johnsrud, Andrew, Ladha, Abdullah, Muffly, Lori, Shiraz, Parveen, Goldstein, Gary, Osgood, Victoria, Shizuru, Judith A., Johnston, Laura, Arai, Sally, Weng, Wen-Kai, Lowsky, Robert, Rezvani, Andrew R., Meyer, Everett H., Frank, Matthew J., Negrin, Robert S., Miklos, David B., and Sidana, Surbhi

Published
2021
Full Text
View/download PDF

49. Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Author

Hamilton, Mark P, Liu-Fei, Felicia C, Alig, Stefan K., Tamaresis, John, Esfahani, Mohammad Shahrokh, Good, Zinaida, Sworder, Brian, Schroers-Martin, Joseph, Liu, Chih Long, Severinsen, Freja Tang, Hanson, Paul J, Lu, Ying, Lowsky, Robert, Negrin, Robert S., Meyer, Everett H, Smith, Melody, Bharadwaj, Sushma, Shizuru, Judith A, Sidana, Surbhi, Shiraz, Parveen, Rezvani, Andrew R., Johnston, Laura J., Weng, Wen-Kai, Arai, Sally, Muffly, Lori, Dahiya, Saurabh, Diehn, Maximilian, Kurtz, David M., Sahaf, Bita, Mackall, Crystal L., Frank, Matthew J, Miklos, David B., and Alizadeh, Ash A.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

50. Immune Phenotypic Quantification of Axicabtagene Ciloleucel and Brexucabtagene Autoleucel Demonstrates Lymphoma Histology Specific Differences in CAR19 Expansion and Toxicity

Author

Hamilton, Mark P., primary, Gentille, Cesar, additional, Mina, Alain, additional, Good, Zinaida, additional, Tamaresis, John, additional, Ehlinger, Zachary, additional, Syal, Shriya, additional, Sworder, Brian, additional, Schroers-Martin, Joseph, additional, Lu, Ying, additional, Muffly, Lori, additional, Negrin, Robert S., additional, Arai, Sally, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Meyer, Everett H., additional, Rezvani, Andrew R., additional, Shizuru, Judith A., additional, Weng, Wen-Kai, additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Bharadwaj, Sushma, additional, Smith, Melody, additional, Dahiya, Saurabh, additional, Sahaf, Bita, additional, Kurtz, David M., additional, Mackall, Crystal, additional, Alizadeh, Ash A., additional, Frank, Matthew J., additional, and Miklos, David B., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results